Skip to content
Politically.com Search all
Menu

2025 · 1st Quarter (Jan 1 - Mar 31)

TRAVERE THERAPEUTICS

Filed by TRAVERE THERAPEUTICS.

Open official filing
Source: Lobbying Disclosure APIRecently refreshed. 2026-08-03 06:26:15 UTC.

Source-reported fields

Filing overview

Type
1st Quarter - Report
Posted
Apr 16, 2025
Income
Not reported
Expenses
$160,000.00
Filing UUID
1609b792-82d5-4214-b33b-d9df2e0fbc5a
Termination date
Not reported

Expense method: A

Literal source text

Lobbying issues and bill citations

HCR · Health Issues

Legislation regarding the Orphan Drug Act and rare disease diagnosis, treatment, and care. Legislation regarding kidney disease and in particular rare kidney disease. HR 1518, the New Era of Preventing End-Stage Kidney Disease Act

Literal federal measure citations: HR 1518

PHA · Pharmacy

HR 946, Optimizing Research Progress Hope and New Cures (ORPHAN Cures Act)

Literal federal measure citations: HR 946

MED · Medical/Disease Research/Clinical Labs

HR 1262, S 932 Give Kids a Chance Act to renew PRV program

Literal federal measure citations: HR 1262, S 932

MMM · Medicare/Medicaid

Regulations regarding transparency, reimbursement and care, particularly regarding rare disease.

CPT · Copyright/Patent/Trademark

S.1040, to prohibit product hopping and for other purposes

Literal federal measure citations: S.1040

TAX · Taxation/Internal Revenue Code

H.R. 1414, Cameron's Law to increase Orphan Drug Tax Credit to 50%

Literal federal measure citations: H.R. 1414

Relationship and amount limits

Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.